Brief: Alto Neuroscience Says Favorable Outcome In Interim Analysis Of ALTO-300 Phase 2B Major Depressive Disorder Trial
12/02/2025 13:14
Feb 12 (Reuters) - Alto Neuroscience ANRO.N :
* ALTO NEUROSCIENCE ANNOUNCES FAVORABLE OUTCOME FROM INTERIM
ANALYSIS OF ALTO-300 PHASE 2B MAJOR DEPRESSIVE DISORDER TRIAL
* ALTO NEUROSCIENCE INC -TOPLINE RESULTS ARE EXPECTED IN
MID-2026
Source text: ID:nBw12H1ra
Further company coverage: ANRO.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alto Neuroscience
See all newsBrief: Alto Neuroscience Promotes Nick Smith To President And Chief Financial Officer
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Brief: Alto Neuroscience - Proposed Resale Of Up To 6 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Brief: Alto Neuroscience Reports Topline Data From Phase 2 Proof-Of-Concept Study Of Alto-101 And Highlights Pipeline Advancements